SCHEMBL3532113

SCHEMBL3532113

CN(CCOc1ccc(CC(=O)O)cc1Br)c1cccc(N(C)CCOc2ccc(CC(=O)O)cc2Br)n1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.44
KDM4E B2RXH2 2/20 0.42
NPY1R P25929 1/20 0.42
NPY2R P49146 1/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LTB4R Q15722 5/20 0.41
LTB4R2 Q9NPC1 5/20 0.41
PTPN11 Q06124 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532111 0.87 HRH3 (0.41) HRH3KDM4EALDH1A1LMNAGAA
SCHEMBL3538793 0.86 LTB4R (0.53) KDM4EALDH1A1LMNATDP1LTB4R
SCHEMBL3531507 0.81 PLA2G4B (0.50) KDM4EALDH1A1LMNALTB4RLTB4R2
SCHEMBL3539135 0.79 LTB4R (0.49) KDM4EL3MBTL1LTB4RLTB4R2SMN1; SMN2
SCHEMBL3542377 0.77 HTR7 (0.37) KDM4ELMNAGAAMAPTHPGD
SCHEMBL17061173 0.76 GAA (0.59) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL3538789 0.75 LTB4R (0.45) KDM4ELTB4RLTB4R2
SCHEMBL3533913 0.74 LTB4R (0.43) KDM4EHPGDL3MBTL1LTB4RLTB4R2
SCHEMBL6255711 0.74 PLA2G4B (0.46) TDP1L3MBTL1LTB4RLTB4R2
SCHEMBL3532524 0.74 PRKAG1 (0.41) GAALTB4RLTB4R2PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP claimed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US claimed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO claimed
US-7816385-B2 Dimeric dicarboxylic acid derivatives, their preparation and use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-10-19 US disclosed
EP-1578716-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2005-09-28 EP disclosed
US-20040259950-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2004-12-23 US disclosed
WO-2004056740-A1 DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259950-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD HRH3 2672/4885KDM4E 3030/4885NPY1R 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.